Sneak Peek from episode VII of my video podcast: Innovating Tomorrow’s Medicine ft. Pilgrim Jackson, CEO of Yatiri Bio Inc. decoding proteins to predict treatment response in Acute Myeloid Leukemia (AML) and Ovarian Cancer.
In this exclusive preview, Pilgrim shares a glimpse into: What proteomic signatures they have found that differentiate responders from non-responders in AML and ovarian cancer. De-risking clinical trial design in oncology, especially with regard to patient heterogeneity.
➡️ Full episode launches on 18 December
🔔 Subscribe and hit the bell so you don’t miss it!
🎙️ About the Show:
Innovating Tomorrow’s Medicine features bold conversations with pioneers shaping the future of healthcare, biotechnology, and life sciences.
📌 Stay tuned for the full interview where we explore and share unique insights:
– What inspired the founding of Yatiri Bio Inc. and decoding proteins to predict treatment response
– Why they chose to focus on AML and ovarian cancer as lead indications
– Proteomics in Oncology
– Targets, Modalities & Resistance
– regulatory strategy, when it comes to stratified trials or biomarker-linked therapies
– Personal reflections and future outlook
#SneakPeek
#PilgrimJackson
#YatiriBio
#FutureOfMedicine